CV Sciences, Inc.

CV Sciences, Inc.

0.01
USD
-0.03
(-79.75%)
-0.01EPS
Apr 01Next Earn

Important Dates

CV Sciences, Inc.'s next confirmed earnings release is scheduled for April 1, 2027.

Earnings Date4/1/2027

Share Statistics

As of June 30, 2026, CV Sciences, Inc. has 213.12M shares outstanding.

Shares Outstanding213.12M

Financial Position

As of June 30, 2026, CV Sciences, Inc. maintains a current ratio of 0.99, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 79.76, indicating elevated leverage, while an interest coverage ratio of -3.68 demonstrates limited ability to service its debt obligations.

Current Ratio0.99
Quick Ratio0.12
Debt / Equity79.76
Debt / EBITDA-1.44
Interest Coverage-3.68

Financial Efficiency

USD

Over the twelve months ended June 30, 2026, CV Sciences, Inc. posted a negative return on equity (ROE) of -118.91, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -27.72, reflecting losses generated across the asset base. The company generates approximately 281,613.26 in revenue per employee across its workforce of 45.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.58 indicates how many times CV Sciences, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-118.91
Return on Assets (ROA)-27.72
Revenue Per Employee281,613.26
Employee Count45.25
Inventory Turnover1.58

Taxes

USD

Over the twelve months ended June 30, 2026, CV Sciences, Inc. recorded 7,000.00 in income tax expense. The company reported a pretax loss of -2.00M and -2.01M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax7,000.00

Stock Price Statistics

USD

As of the close on November 9, 2026, CV Sciences, Inc.'s stock has declined approximately 84.00% over the past 52 weeks.

52-Week Price Change-84.00%
50-Day Moving Average0.05

Income Statement

USD

Over the twelve months ended June 30, 2026, CV Sciences, Inc. generated 12.74M in revenue and converted that into -2.01M in net income, yielding earnings per share of -0.01. EBITDA reached -872,000.00, while operating income came in at -969,000.00.

Revenue12.74M
Gross Profit6.26M
Operating Income-969,000.00
Pretax Income-2.00M
Net Income-2.01M
EBITDA-872,000.00
EBIT-969,000.00
Earnings Per Share (EPS)-0.01

Balance Sheet

USD

As of June 30, 2026, CV Sciences, Inc. holds 266,000.00 in cash and equivalents against 1.25M in total debt, resulting in a net debt position of 769,000.00. Total book value stands at 1.57M, with working capital of -64,000.00 providing operational flexibility.

Cash & Cash Equivalents266,000.00
Total Debt1.25M
Net Debt769,000.00
Equity (Book Value)1.57M
Book Value Per Share0.01
Working Capital-64,000.00

Cash Flow

USD

CV Sciences, Inc. produced -492,000.00 in operating cash flow over the twelve months ended June 30, 2026. After subtracting -30,000.00 in capital expenditures, free cash flow totaled -522,000.00 - equivalent to 0.00 per share.

Operating Cash Flow-492,000.00
Capital Expenditures-30,000.00
Free Cash Flow-522,000.00

Margins

Over the twelve months ended June 30, 2026, CV Sciences, Inc. posted a gross margin of 49.14, reflecting its pricing power and cost economics. The operating margin of -7.60 and net profit margin of -15.74 provide insight into operational efficiency.

Gross Margin49.14
Operating Margin-7.60
Pretax Margin-15.69
Profit Margin-15.74
EBITDA Margin-6.84